Switch theme
Sign up to access all valuation multiples
Oncoclinicas Do Brasil Servicos Medicos SA is engaged in the management and administration of oncological services. It has specialists in the areas of oncology, radiotherapy, hematology and bone marrow transplantation, complementary care.
2010
3.7K+
LTM Revenue $1.2B
LTM EBITDA $184M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oncoclinicas Do Brasil has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $184M.
In the most recent fiscal year, Oncoclinicas Do Brasil achieved revenue of $1.1B and an EBITDA of $49.9M.
Oncoclinicas Do Brasil expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oncoclinicas Do Brasil valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $401M | XXX | $379M | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $184M | XXX | $49.9M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 4% | XXX | XXX | XXX |
| EBIT | $59.8M | XXX | -$26.3M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | -2% | XXX | XXX | XXX |
| Net Profit | -$10.3M | XXX | -$119M | XXX | XXX | XXX |
| Net Margin | -1% | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $803M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Oncoclinicas Do Brasil's stock price is BRL 5 (or $1).
Oncoclinicas Do Brasil has current market cap of BRL 3.4B (or $626M), and EV of BRL 7.7B (or $1.4B).
See Oncoclinicas Do Brasil trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $626M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Oncoclinicas Do Brasil has market cap of $626M and EV of $1.4B.
Oncoclinicas Do Brasil's trades at 1.2x EV/Revenue multiple, and 28.6x EV/EBITDA.
Equity research analysts estimate Oncoclinicas Do Brasil's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncoclinicas Do Brasil has a P/E ratio of -61.1x.
See valuation multiples for Oncoclinicas Do Brasil and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $626M | XXX | $626M | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 7.8x | XXX | 28.6x | XXX | XXX | XXX |
| EV/EBIT | 23.8x | XXX | -54.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -61.1x | XXX | -5.3x | XXX | XXX | XXX |
| EV/FCF | 30.0x | XXX | -19.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOncoclinicas Do Brasil's last 12 month revenue growth is 8%
Oncoclinicas Do Brasil's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Oncoclinicas Do Brasil's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oncoclinicas Do Brasil's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oncoclinicas Do Brasil and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | -12% | XXX | XXX | XXX |
| Rule of 40 | 28% | XXX | 12% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncoclinicas Do Brasil acquired XXX companies to date.
Last acquisition by Oncoclinicas Do Brasil was XXXXXXXX, XXXXX XXXXX XXXXXX . Oncoclinicas Do Brasil acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Oncoclinicas Do Brasil founded? | Oncoclinicas Do Brasil was founded in 2010. |
| Where is Oncoclinicas Do Brasil headquartered? | Oncoclinicas Do Brasil is headquartered in Brazil. |
| How many employees does Oncoclinicas Do Brasil have? | As of today, Oncoclinicas Do Brasil has 3.7K+ employees. |
| Who is the CEO of Oncoclinicas Do Brasil? | Oncoclinicas Do Brasil's CEO is Mr. Bruno Lemos Ferrari. |
| Is Oncoclinicas Do Brasil publicy listed? | Yes, Oncoclinicas Do Brasil is a public company listed on BVMF. |
| What is the stock symbol of Oncoclinicas Do Brasil? | Oncoclinicas Do Brasil trades under ONCO3 ticker. |
| When did Oncoclinicas Do Brasil go public? | Oncoclinicas Do Brasil went public in 2021. |
| Who are competitors of Oncoclinicas Do Brasil? | Similar companies to Oncoclinicas Do Brasil include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Oncoclinicas Do Brasil? | Oncoclinicas Do Brasil's current market cap is $626M |
| What is the current revenue of Oncoclinicas Do Brasil? | Oncoclinicas Do Brasil's last 12 months revenue is $1.2B. |
| What is the current revenue growth of Oncoclinicas Do Brasil? | Oncoclinicas Do Brasil revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Oncoclinicas Do Brasil? | Current revenue multiple of Oncoclinicas Do Brasil is 1.2x. |
| Is Oncoclinicas Do Brasil profitable? | Yes, Oncoclinicas Do Brasil is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Oncoclinicas Do Brasil? | Oncoclinicas Do Brasil's last 12 months EBITDA is $184M. |
| What is Oncoclinicas Do Brasil's EBITDA margin? | Oncoclinicas Do Brasil's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Oncoclinicas Do Brasil? | Current EBITDA multiple of Oncoclinicas Do Brasil is 7.8x. |
| What is the current FCF of Oncoclinicas Do Brasil? | Oncoclinicas Do Brasil's last 12 months FCF is $47.6M. |
| What is Oncoclinicas Do Brasil's FCF margin? | Oncoclinicas Do Brasil's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Oncoclinicas Do Brasil? | Current FCF multiple of Oncoclinicas Do Brasil is 30.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
